Bimekizumab’s efficacy ‘favorable’ in psoriatic arthritis vs other approved treatments
Click Here to Manage Email Alerts
Key takeaways:
- Bimekizumab ranked favorably among all other approved PsA treatments on joint, skin and minimal disease activity outcomes.
- The drug’s safety profile was comparable to other treatments.
Bimekizumab’s efficacy in psoriatic arthritis is “favorable” when compared with all other approved treatments in terms of both efficacy and safety, according to a systemic review and network meta-analysis published in Rheumatology.
“Despite the number of available treatment options, the majority of patients with PsA report that they do not achieve remission and additional therapeutic options are needed,” Philip J. Mease, MD, of the Swedish Medical Center and the University of Washington, in Seattle, and colleagues wrote. “The treatment landscape for PsA continues to evolve, and treatment decisions increase in complexity, especially as direct comparative data are limited.”
To evaluate the efficacy and safety of bimekizumab (Bimzelx, UCB) 160 mg every 4 weeks for PsA, compared with other biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), Mease and colleagues conducted a systematic literature review. The researchers assessed studies evaluating various PsA treatments, then used Bayesian network meta-analysis to compare their performance in subgroups of patients who are naïve to biologic/targeted synthetic DMARDs, as well as those experienced with TNF inhibitors.
Outcomes in each population included ACR 20/50/70 responses, Psoriasis Area and Severity Index (PASI90/100) response and minimal disease activity. Serious adverse events were analyzed using a mixed set of all subgroups’ data.
A total of 41 studies met criteria for inclusion in network meta-analysis. Evaluated therapies included abatacept (Orencia, Bristol Myers Squibb), adalimumab (Humira, AbbVie), apremilast (Otezla, Celgene), bimekizumab, certolizumab pegol (Cimzia, UCB), etanercept (Enbrel, Amgen), golimumab (Simponi, Janssen), guselkumab (Tremfya, Janssen), infliximab (Remicade, Janssen), ixekizumab (Taltz, Eli Lilly & Co.), Risankizumab (Skyrizi, AbbVie), secukinumab (Cosentyx, Novartic), tofacitinib (Xeljanz, Pfizer), Upadacitinib (Rinvoq, AbbVie), ustekinumab (Stelara, Janssen) and placebo.
According to the researchers, bimekizumab ranked first among biologic/targeted synthetic DMARD-naïve patients, and second among those who had received TNF inhibitors regarding minimal disease activity. For ACR 20/50/70 response among DMARD-naïve patients, bimekizumab ranked sixth, fifth and third, respectively, while the drug finished first, second and first among those who were experienced with TNF inhibitors. Regarding PSAI90/100, bimekizumab ranked second and first among the DMARD-naïve patients, respectively, and first and second for TNF inhibitor-experienced-patients.
Meanwhile, bimekizumab demonstraed “comparable safety” with 23 other treatments in the network analyzing serious adverse events in a mixed population, the researchers wrote.
“The results of this [network meta-analysis] demonstrate the favorable relative efficacy and safety of bimekizumab 160 mg [every 4 weeks] vs. all approved treatments for PsA,” Mease and colleagues wrote. “In the evolving PsA treatment landscape, bimekizumab 160 mg [every 4 weeks] is a potentially beneficial treatment option for patients with PsA.”
Collapse
Read more about
Click Here to Manage Email Alerts